Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cellceutix Corp.

Developing a still-secret prodrug for psoriasis, and a heralded cancer candidate

This article was originally published in Start Up

Executive Summary

These days, most start-up companies intent on developing a novel treatment for nearly any disease make a point of talking about their drug candidate’s presumed mechanism of action. It is pretty much de rigueur that a would-be drugmaker will discuss molecular something: if not the candidate itself, then certainly its target. But Cellceutix Corp. is not a typical start-up. Founded in June 2007, it became a publicly traded company through a reverse merger in December of that year. While the company appreciates the buzz that its anti-cancer candidate is generating, it is being a bit more tight-lipped about Prurisol, its novel drug candidate for psoriasis.

You may also be interested in...

Cellceutix Buys Mid-Stage Antibiotic Brilacidin On The Cheap

With brilacidin developer PolyMedix having filed for bankruptcy, Cellceutix will acquire the company’s assets for $2.1 million in cash and 1.4 million shares of stock.

New Orals, Better Topicals Top Psoriasis Wish List

Biologics for psoriasis leapfrogged existing treatments in the last decade, greatly improving the standard of care. Although those may still see incremental improvements, the real changes for patient care may come with the introduction of new oral and topical treatments. START-UP profiles four emerging companies that are tackling this challenge: Avexxin, Cellceutix, Creabilis, and Convoy Therapeutics.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts